Exelixis Inc. EXEL, -1.66% shares fell in the extended session Thursday after the biotech drug maker said a late-stage clinical trial of its kidney cancer drug treatment did not meet its endpoint. Exelixis shares fell 6% after hours, following a 1.7% decline to close the regular session at $17.18. In the 522-patient study, kidney cancer patients were either given cabozantinib and standard treatment or a placebo and standard treatment. Exelixis said it will release detailed findings at a medical meeting soon but stated that patients in the cabozantinib cohort did not survive without disease progression any better than those given the placebo.
This article was originally published by Marketwatch.com. Read the original article here.
